Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of the firm’s stock in a transaction dated Friday, January 8th. The stock was sold at an average price of $28.12, for a total value of $281,200.00. Following the transaction, the chief operating officer now owns 189,285 shares of the company’s stock, valued at $5,322,694.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Jonathan Young also recently made the following trade(s):
- On Monday, January 4th, Jonathan Young sold 3,060 shares of Akero Therapeutics stock. The stock was sold at an average price of $25.29, for a total value of $77,387.40.
Shares of NASDAQ:AKRO opened at $28.31 on Thursday. The company has a market cap of $982.98 million, a PE ratio of -13.05 and a beta of 0.58. The stock’s 50-day moving average is $27.33 and its 200 day moving average is $30.91. Akero Therapeutics, Inc. has a 1 year low of $10.78 and a 1 year high of $41.16.
Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Tuesday, November 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.04). Equities research analysts anticipate that Akero Therapeutics, Inc. will post -2.22 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on the stock. HC Wainwright upped their price objective on shares of Akero Therapeutics from $62.00 to $64.00 and gave the company a “buy” rating in a report on Friday, November 13th. Zacks Investment Research upgraded Akero Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub downgraded Akero Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 31st. Finally, ValuEngine raised shares of Akero Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, December 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Akero Therapeutics currently has an average rating of “Buy” and an average price target of $54.71.
Several hedge funds have recently bought and sold shares of AKRO. Alkeon Capital Management LLC lifted its position in Akero Therapeutics by 128.4% during the third quarter. Alkeon Capital Management LLC now owns 2,280,707 shares of the company’s stock valued at $70,223,000 after purchasing an additional 1,282,333 shares during the period. Apple Tree Partners IV L.P. lifted its position in shares of Akero Therapeutics by 7.7% in the third quarter. Apple Tree Partners IV L.P. now owns 5,830,203 shares of the company’s stock valued at $179,512,000 after acquiring an additional 415,000 shares in the last quarter. Boxer Capital LLC boosted its stake in Akero Therapeutics by 99.6% in the 3rd quarter. Boxer Capital LLC now owns 831,495 shares of the company’s stock worth $25,602,000 after purchasing an additional 415,000 shares during the period. BlackRock Inc. boosted its position in shares of Akero Therapeutics by 31.4% during the third quarter. BlackRock Inc. now owns 1,353,758 shares of the company’s stock worth $41,681,000 after acquiring an additional 323,776 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Akero Therapeutics during the 2nd quarter valued at about $1,607,000. Hedge funds and other institutional investors own 83.49% of the company’s stock.
Akero Therapeutics Company Profile
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc and changed its name to Akero Therapeutics, Inc in May 2018.
Read More: What is Blockchain?
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.